Founded in 2010, Althera is a Pharmaceutical R&D and commercialization organization. Our mission is to make significant positive impact on lives of patients by bringing to market innovative and complex products through our own development and in partnerships with other innovators.

Our Portfolio

Althera received approval of its own development product AL-320 (rosuvastatin/ezetimibe tablets) in 2017 in major European markets. Additionally AL-110 (metformin XR/rosuvastatin tablets) is currently in registration phase in Europe and other markets. AL-310 (atorvastatin/ezetimibe) product is in the final development stage and is expected to be filed in major markets in 2017.

Additionally several projects are in early stage of development.

We also undertake extensive licensing and acquisition activities to bring specialty products to market that make significant positive impact on the lives of patients we aim to serve.

Our Values

Althera instituted our values in 2010, the year Althera began its journey. These values have guided us since then and will guide our actions in the years to come. These values center around Patients, our commitment to Innovation, Excellence and Quality, and to Passion and People.